Rezdiffra专利获胜后马德里加尔获利

2025-07-16 20:54

Madrigal Pharmaceuticals (NASDAQ:MDGL) traded higher in the premarket on Wednesday after the company announced a patent win related to its lead asset, Rezdiffra, approved by the FDA in 2024 for a liver condition known as MASH.
According to the company, the U.S. Patent and Trademark Office has issued a notice of allowance informing it of a new patent scheduled to be issued in relation to Rezdiffra, a once-daily oral therapy targeted at the thyroid hormone receptor beta (THR-β).
“The Notice of Allowance includes claims directed to Rezdiffra’s commercial weight-threshold dosing regimen as prescribed in the FDA-approved label,” Madrigal (NASDAQ:MDGL) said.
The U.S. patent, which expires on Sept. 30, 2044, will also be listed in the FDA’s Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations), which details patent and exclusivity information related to the drugs approved by the agency.

More on Madrigal Pharmaceuticals, Inc.